TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Comparison of Symbicort Single Inhaler Therapy (Symbicort Turbohaler 160/4.5 μg, 1 Inhalation b.i.d. Plus as Needed) and Conventional Best Practice for the Treatment of Persistent Asthma in Adolescents and Adults - a 26-week, Randomised, Open-label, Parallel-group, Multi-centre Study (SALTO)
Brief Summary: The primary objective is to compare the efficacy of Symbicort Single inhaler Therapy with treatment according to conventional best practice in adolescent and adult patients with persistent asthma.


Options:
A: Arm Label: Daily ICS + Rescue ICS; Type: EXPERIMENTAL; Interventions: Drug: Beclomethasone dipropionate, Drug: Albuterol sulfate | Arm Label: Daily ICS; Type: ACTIVE_COMPARATOR; Interventions: Drug: Beclomethasone dipropionate, Drug: Albuterol sulfate | Arm Label: Rescue ICS; Type: EXPERIMENTAL; Interventions: Drug: Beclomethasone dipropionate, Drug: Albuterol sulfate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Albuterol sulfate | Intervention Type: DRUG; Name: Beclomethasone dipropionate; Assigned to Arm(s): Daily ICS, Daily ICS + Rescue ICS | Intervention Type: DRUG; Name: Beclomethasone dipropionate; Assigned to Arm(s): Daily ICS + Rescue ICS, Rescue ICS | Intervention Type: DRUG; Name: Albuterol sulfate; Assigned to Arm(s): Daily ICS, Daily ICS + Rescue ICS, Placebo, Rescue ICS
B: Intervention Type: DRUG; Name: inhaled corticosteroids; Assigned to Arm(s): N/A
C: Arm Label: Placebo Budesonide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Budesonide, Drug: Placebo Budesonide | Arm Label: Budesonide; Type: EXPERIMENTAL; Interventions: Drug: Budesonide, Drug: Placebo Budesonide | Intervention Type: DRUG; Name: Budesonide; Assigned to Arm(s): Budesonide, Placebo Budesonide | Intervention Type: DRUG; Name: Placebo Budesonide; Assigned to Arm(s): Budesonide, Placebo Budesonide
D: Intervention Type: DRUG; Name: Budesonide/formoterol; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase IIB Study to Assess the Efficacy of GSK 249553 as Adjuvant Therapy Given to MAGE-3-Positive Patients With Non-Small-Cell Lung Cancer in Stage IB (T2/N0) or II (T1/N1 or T2/N1 or T3/N0), Who Have Had Complete Surgical Resection
Brief Summary: Patients will receive injections of GSK 249553 vaccine . Appropriate tests will be performed to assess the safety of the treatment and its ability to induce an immune response.


Options:
A: Arm Label: Tecemotide (L-BLP25); Type: EXPERIMENTAL; Interventions: Biological: Tecemotide (L-BLP25), Drug: Single low dose cyclophosphamide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: BIOLOGICAL; Name: Tecemotide (L-BLP25); Assigned to Arm(s): Tecemotide (L-BLP25) | Intervention Type: DRUG; Name: Single low dose cyclophosphamide; Assigned to Arm(s): Tecemotide (L-BLP25) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Investigational Arm; Type: EXPERIMENTAL; Interventions: Biological: Tecemotide, Drug: Single low dose cyclophosphamide, Other: Best Supportive Care (BSC) | Arm Label: Control Arm; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Other: Saline, Other: Best Supportive Care (BSC) | Intervention Type: BIOLOGICAL; Name: Tecemotide; Assigned to Arm(s): Investigational Arm | Intervention Type: DRUG; Name: Single low dose cyclophosphamide; Assigned to Arm(s): Investigational Arm | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Control Arm | Intervention Type: OTHER; Name: Saline; Assigned to Arm(s): Control Arm | Intervention Type: OTHER; Name: Best Supportive Care (BSC); Assigned to Arm(s): Control Arm, Investigational Arm
C: Arm Label: GSK 249553 Group; Type: EXPERIMENTAL; Interventions: Biological: GSK 249553 vaccine | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: GSK 249553 vaccine; Assigned to Arm(s): GSK 249553 Group | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo Group
D: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: PF-3512676 + Erlotinib | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Erlotinib | Intervention Type: DRUG; Name: PF-3512676 + Erlotinib; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Erlotinib; Assigned to Arm(s): B

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Digestive and Nutritional Effects of Probiotics (Bifidobacterium Longum and Lactobacillus GG) Supplementation in Premature Newborns
Brief Summary: Symbiotic interaction between probiotics ("Living alimentary microbials supplemental, affecting positively host by improving intestinal microbial equilibrium" (Fuller, 1989)) and human digestive tract was amply experimented and seems to be an interesting solution to orientate neonates digestive flora. Many studies showed a probant efficiency of probiotic supplementation in neonates on ECUN, despite abnormally high ECUN incidence in control group. Nevertheless, our aim is to test clinical efficiency of two new probiotics strains. Bifidobacterium Longum and Lactobacillus GG on Oral Nutrition (volume at Day 14 and Day 21) and safety (Adverse Events) in very premature babies.


Options:
A: Intervention Type: DIETARY_SUPPLEMENT; Name: Probiotics supplementation until weight reaches 1800g (Bifidobacterium Longum and Lactobacillus GG ); Assigned to Arm(s): N/A
B: Arm Label: Probiotics; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Probiotics | Arm Label: Probiotics + Dietary counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Dietary counselling and probiotics | Arm Label: Dietary counseling + placebo; Type: EXPERIMENTAL; Interventions: Behavioral: Dietary counselling and placebo | Arm Label: Prebiotics; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Prebiotics | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo capsules | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Dietary counselling and placebo; Assigned to Arm(s): Dietary counseling + placebo | Intervention Type: BEHAVIORAL; Name: Dietary counselling and probiotics; Assigned to Arm(s): Probiotics + Dietary counseling | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo capsules; Assigned to Arm(s): Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Probiotics; Assigned to Arm(s): Probiotics | Intervention Type: DIETARY_SUPPLEMENT; Name: Prebiotics; Assigned to Arm(s): Prebiotics
C: Arm Label: Lactobacillus reuteri; Type: EXPERIMENTAL; Interventions: Drug: Lactobacillus reuteri | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Lactobacillus reuteri; Assigned to Arm(s): Lactobacillus reuteri | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Control
D: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Lactobacillus reuteri | Intervention Type: DIETARY_SUPPLEMENT; Name: Lactobacillus reuteri; Assigned to Arm(s): 2 | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): 1

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Digestive and Nutritional Effects of Probiotics (Bifidobacterium Longum and Lactobacillus GG) Supplementation in Premature Newborns
Brief Summary: Symbiotic interaction between probiotics ("Living alimentary microbials supplemental, affecting positively host by improving intestinal microbial equilibrium" (Fuller, 1989)) and human digestive tract was amply experimented and seems to be an interesting solution to orientate neonates digestive flora. Many studies showed a probant efficiency of probiotic supplementation in neonates on ECUN, despite abnormally high ECUN incidence in control group. Nevertheless, our aim is to test clinical efficiency of two new probiotics strains. Bifidobacterium Longum and Lactobacillus GG on Oral Nutrition (volume at Day 14 and Day 21) and safety (Adverse Events) in very premature babies.


Options:
A: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Lactobacillus reuteri | Intervention Type: DIETARY_SUPPLEMENT; Name: Lactobacillus reuteri; Assigned to Arm(s): 2 | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): 1
B: Arm Label: Lactobacillus reuteri; Type: EXPERIMENTAL; Interventions: Drug: Lactobacillus reuteri | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Lactobacillus reuteri; Assigned to Arm(s): Lactobacillus reuteri | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Control
C: Arm Label: 2; Type: EXPERIMENTAL; Interventions: Dietary Supplement: infloran | Intervention Type: DIETARY_SUPPLEMENT; Name: infloran; Assigned to Arm(s): 2 | Intervention Type: DIETARY_SUPPLEMENT; Name: infloran; Assigned to Arm(s): 2
D: Intervention Type: DIETARY_SUPPLEMENT; Name: Probiotics supplementation until weight reaches 1800g (Bifidobacterium Longum and Lactobacillus GG ); Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Glycine vs Placebo for the Schizophrenia Prodrome
Brief Summary: Glycine is a natural amino acid neurotransmitter that acts as a co-agonist at NMDA receptors in brain. We hypothesize that symptoms of the schizophrenia prodrome will improve with glycine to a greater degree than with placebo.


Options:
A: Arm Label: Glycine; Type: EXPERIMENTAL; Interventions: Drug: Glycine | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Glycine; Assigned to Arm(s): Glycine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Group
B: Arm Label: Family Focused Treatment; Type: EXPERIMENTAL; Interventions: Behavioral: Family Focused Treatment | Arm Label: Enhanced Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Enhanced Care | Intervention Type: BEHAVIORAL; Name: Family Focused Treatment; Assigned to Arm(s): Family Focused Treatment | Intervention Type: BEHAVIORAL; Name: Enhanced Care; Assigned to Arm(s): Enhanced Care
C: Arm Label: Standard treatment + cognitive remediation; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive remediation, Behavioral: Standard treatment | Arm Label: Standard treatment; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard treatment | Intervention Type: BEHAVIORAL; Name: Cognitive remediation; Assigned to Arm(s): Standard treatment + cognitive remediation | Intervention Type: BEHAVIORAL; Name: Standard treatment; Assigned to Arm(s): Standard treatment, Standard treatment + cognitive remediation
D: Intervention Type: BEHAVIORAL; Name: Integrated treatment, family involvement; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Social skills training; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Randomised, Double Blind, Parallel-group Study of the Efficacy and Safety of Oral Dabigatran Etexilate 150 mg Twice Daily Compared to Warfarin (INR 2.0-3.0) for 6 Month Treatment of Acute Symptomatic Venous Thromboembolism (VTE), Following Initial Treatment (5-10 Days) With a Parenteral Anticoagulant Approved for This Indication.
Brief Summary: The purpose of this trial is to determine the comparative safety and efficacy of dabigatran etexilate 150 mg bid administered orally and warfarin as needed (pro re nata - prn) to maintain an International Normalised Ratio (INR) of 2.0-3.0 for 6 month treatment of acute symptomatic venous thromboembolism (VTE), following initial treatment (5-10 days) with a parenteral anticoagulant approved for this indication. This trial aims to demonstrate non-inferiority of dabigatran compared with warfarin in patients with acute symptomatic VTE. After achieving non-inferiority, this trial also aims to establish superiority (by means of hierarchical tests) of dabigatran over warfarin.


Options:
A: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lenalidomide, Drug: Prednisone, Drug: Melphalan | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Melphalan | Intervention Type: DRUG; Name: Melphalan; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Lenalidomide; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Prednisone; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Melphalan; Assigned to Arm(s): A
B: Arm Label: GFFC + LMWH; Type: EXPERIMENTAL; Interventions: Drug: Enoxaparine | Intervention Type: DRUG; Name: Enoxaparine; Assigned to Arm(s): GFFC + LMWH
C: Arm Label: Edoxaban group; Type: EXPERIMENTAL; Interventions: Drug: Edoxaban, Drug: Low molecular weight heparin | Arm Label: Dalteparin group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dalteparin | Intervention Type: DRUG; Name: Edoxaban; Assigned to Arm(s): Edoxaban group | Intervention Type: DRUG; Name: Dalteparin; Assigned to Arm(s): Dalteparin group | Intervention Type: DRUG; Name: Low molecular weight heparin; Assigned to Arm(s): Edoxaban group
D: Arm Label: dabigatran etexilate 150 mg; Type: EXPERIMENTAL; Interventions: Drug: dabigatran etexilate 150 mg | Arm Label: warfarin (INR 2-3); Type: ACTIVE_COMPARATOR; Interventions: Drug: warfarin (INR 2-3) | Intervention Type: DRUG; Name: dabigatran etexilate 150 mg; Assigned to Arm(s): dabigatran etexilate 150 mg | Intervention Type: DRUG; Name: warfarin (INR 2-3); Assigned to Arm(s): warfarin (INR 2-3)

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Randomised, Double Blind, Parallel-group Study of the Efficacy and Safety of Oral Dabigatran Etexilate 150 mg Twice Daily Compared to Warfarin (INR 2.0-3.0) for 6 Month Treatment of Acute Symptomatic Venous Thromboembolism (VTE), Following Initial Treatment (5-10 Days) With a Parenteral Anticoagulant Approved for This Indication.
Brief Summary: The purpose of this trial is to determine the comparative safety and efficacy of dabigatran etexilate 150 mg bid administered orally and warfarin as needed (pro re nata - prn) to maintain an International Normalised Ratio (INR) of 2.0-3.0 for 6 month treatment of acute symptomatic venous thromboembolism (VTE), following initial treatment (5-10 days) with a parenteral anticoagulant approved for this indication. This trial aims to demonstrate non-inferiority of dabigatran compared with warfarin in patients with acute symptomatic VTE. After achieving non-inferiority, this trial also aims to establish superiority (by means of hierarchical tests) of dabigatran over warfarin.


Options:
A: Arm Label: Dabigatran; Type: EXPERIMENTAL; Interventions: Drug: Dabigatran | Arm Label: Warfarin (INR of 2.0-3.0); Type: ACTIVE_COMPARATOR; Interventions: Drug: Warfarin | Intervention Type: DRUG; Name: Dabigatran; Assigned to Arm(s): Dabigatran | Intervention Type: DRUG; Name: Warfarin; Assigned to Arm(s): Warfarin (INR of 2.0-3.0)
B: Arm Label: Dabigatran etexilate (150mg bid); Type: EXPERIMENTAL; Interventions: Drug: Dabigatran etexilate | Arm Label: Warfarin (INR 2.0-3.0); Type: ACTIVE_COMPARATOR; Interventions: Drug: Warfarin | Intervention Type: DRUG; Name: Warfarin; Assigned to Arm(s): Warfarin (INR 2.0-3.0) | Intervention Type: DRUG; Name: Dabigatran etexilate; Assigned to Arm(s): Dabigatran etexilate (150mg bid)
C: Arm Label: dabigatran etexilate 150 mg; Type: EXPERIMENTAL; Interventions: Drug: dabigatran etexilate 150 mg | Arm Label: warfarin (INR 2-3); Type: ACTIVE_COMPARATOR; Interventions: Drug: warfarin (INR 2-3) | Intervention Type: DRUG; Name: dabigatran etexilate 150 mg; Assigned to Arm(s): dabigatran etexilate 150 mg | Intervention Type: DRUG; Name: warfarin (INR 2-3); Assigned to Arm(s): warfarin (INR 2-3)
D: Arm Label: Apixaban; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin, Drug: warfarin, Drug: Placebo for apixaban | Arm Label: Enoxaparin + Warfarin; Type: EXPERIMENTAL; Interventions: Drug: Placebo for enoxaparin, Drug: Placebo for warfarin, Drug: apixaban | Intervention Type: DRUG; Name: Enoxaparin; Assigned to Arm(s): Apixaban | Intervention Type: DRUG; Name: warfarin; Assigned to Arm(s): Apixaban | Intervention Type: DRUG; Name: Placebo for apixaban; Assigned to Arm(s): Apixaban | Intervention Type: DRUG; Name: Placebo for enoxaparin; Assigned to Arm(s): Enoxaparin + Warfarin | Intervention Type: DRUG; Name: Placebo for warfarin; Assigned to Arm(s): Enoxaparin + Warfarin | Intervention Type: DRUG; Name: apixaban; Assigned to Arm(s): Enoxaparin + Warfarin

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Randomised, Double Blind, Parallel-group Study of the Efficacy and Safety of Oral Dabigatran Etexilate 150 mg Twice Daily Compared to Warfarin (INR 2.0-3.0) for 6 Month Treatment of Acute Symptomatic Venous Thromboembolism (VTE), Following Initial Treatment (5-10 Days) With a Parenteral Anticoagulant Approved for This Indication.
Brief Summary: The purpose of this trial is to determine the comparative safety and efficacy of dabigatran etexilate 150 mg bid administered orally and warfarin as needed (pro re nata - prn) to maintain an International Normalised Ratio (INR) of 2.0-3.0 for 6 month treatment of acute symptomatic venous thromboembolism (VTE), following initial treatment (5-10 days) with a parenteral anticoagulant approved for this indication. This trial aims to demonstrate non-inferiority of dabigatran compared with warfarin in patients with acute symptomatic VTE. After achieving non-inferiority, this trial also aims to establish superiority (by means of hierarchical tests) of dabigatran over warfarin.


Options:
A: Arm Label: Rivaroxaban (Xarelto, BAY59-7939); Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Rivaroxaban (Xarelto, BAY59-7939); Assigned to Arm(s): Rivaroxaban (Xarelto, BAY59-7939) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: dabigatran etexilate 150 mg; Type: EXPERIMENTAL; Interventions: Drug: dabigatran etexilate 150 mg | Arm Label: warfarin (INR 2-3); Type: ACTIVE_COMPARATOR; Interventions: Drug: warfarin (INR 2-3) | Intervention Type: DRUG; Name: dabigatran etexilate 150 mg; Assigned to Arm(s): dabigatran etexilate 150 mg | Intervention Type: DRUG; Name: warfarin (INR 2-3); Assigned to Arm(s): warfarin (INR 2-3)
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Apixaban | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Apixaban | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Apixaban; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3
D: N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Randomised, Double Blind, Parallel-group Study of the Efficacy and Safety of Oral Dabigatran Etexilate 150 mg Twice Daily Compared to Warfarin (INR 2.0-3.0) for 6 Month Treatment of Acute Symptomatic Venous Thromboembolism (VTE), Following Initial Treatment (5-10 Days) With a Parenteral Anticoagulant Approved for This Indication.
Brief Summary: The purpose of this trial is to determine the comparative safety and efficacy of dabigatran etexilate 150 mg bid administered orally and warfarin as needed (pro re nata - prn) to maintain an International Normalised Ratio (INR) of 2.0-3.0 for 6 month treatment of acute symptomatic venous thromboembolism (VTE), following initial treatment (5-10 days) with a parenteral anticoagulant approved for this indication. This trial aims to demonstrate non-inferiority of dabigatran compared with warfarin in patients with acute symptomatic VTE. After achieving non-inferiority, this trial also aims to establish superiority (by means of hierarchical tests) of dabigatran over warfarin.


Options:
A: Arm Label: dabigatran etexilate 150 mg; Type: EXPERIMENTAL; Interventions: Drug: dabigatran etexilate 150 mg | Arm Label: warfarin (INR 2-3); Type: ACTIVE_COMPARATOR; Interventions: Drug: warfarin (INR 2-3) | Intervention Type: DRUG; Name: dabigatran etexilate 150 mg; Assigned to Arm(s): dabigatran etexilate 150 mg | Intervention Type: DRUG; Name: warfarin (INR 2-3); Assigned to Arm(s): warfarin (INR 2-3)
B: Arm Label: Clopidogrel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Clopidogrel | Arm Label: Ticagrelor; Type: EXPERIMENTAL; Interventions: Drug: Ticagrelor | Intervention Type: DRUG; Name: Ticagrelor; Assigned to Arm(s): Ticagrelor | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): Clopidogrel
C: Arm Label: Rivaroxaban (Xarelto, BAY59-7939); Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939) | Arm Label: Enoxaparin/VKA; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin overlapping with and followed by VKA | Intervention Type: DRUG; Name: Rivaroxaban (Xarelto, BAY59-7939); Assigned to Arm(s): Rivaroxaban (Xarelto, BAY59-7939) | Intervention Type: DRUG; Name: Enoxaparin overlapping with and followed by VKA; Assigned to Arm(s): Enoxaparin/VKA
D: Arm Label: Enoxaparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: enoxaparin | Arm Label: Fondaparinux; Type: EXPERIMENTAL; Interventions: Drug: Fondaparinux | Intervention Type: DRUG; Name: Fondaparinux; Assigned to Arm(s): Fondaparinux | Intervention Type: DRUG; Name: enoxaparin; Assigned to Arm(s): Enoxaparin

Answer: A